送交者: lijun 于 2006-4-17, 11:56:06:
回答: You are wrong!! 自2000年发表至今，该文被国际期刊引用58次。 由 sisi1 于 2006-4-16, 13:31:56:
1. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2.
Author(s)
Luo-Y, Wen-Y-J, Ding-Z-Y, Fu-C-H, Wu-Y, Liu-J-Y, Li-Q, He-Q-M, Zhao-X, Jiang-Y, Li-J, Deng-H-X, Kang-B, Mao-Y-Q, Wei-Y-Q.
Source
CLINICAL-CANCER-RESEARCH, 2006, V12, N6, MAR 15, pp 1813-1819 ISSN: 1078-0432.
Number of cited refs.
41 references.
2. The kinase insert domain-containing receptor is an angiogenesis- associated antigen recognized by human cytotoxic T lymphocytes.
Author(s)
Sun-Y-S, Stevanovic-S, Song-M-X, Schwantes-A, Kirkpatrick-C-J, Schadendorf-D, Cichutek-K.
Source
BLOOD, 2006, V107, N4, FEB 15, pp 1476-1483 ISSN: 0006-4971.
Number of cited refs.
43 references.
3. Human T lymphocyte responses against lung cancer induced by recombinant truncated mouse EGFR.
Author(s)
Hu-B, Wei-Y-Q, Tian-L, Zhao-X, Lu-Y, Wu-Y, Yao-B, Zhang-X-W.
Source
CANCER-IMMUNOLOGY-IMMUNOTHERAPY, 2006, V55, N4, APR, pp 386-393 ISSN: 0340-7004.
Number of cited refs.
46 references.
4. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Author(s)
Lee-J, Fassnacht-M, Nair-S, Boczkowski-D, Gilboa-E.
Source
CANCER-RESEARCH, 2005, V65, N23, DEC 1, pp 11156-11163 ISSN: 0008-5472.
Number of cited refs.
48 references.
5. Xenogenic smooth muscle cell immunization reduces neointimal formation in balloon-injured rabbit carotid arteries.
Author(s)
Shinohara-M, Kawashima-S, Yamashita-T, Takaya-T, Toh-R, Ishida-T, Ueyama-T, Inoue-N, Hirata-K-I, Yokoyama-M.
Source
CARDIOVASCULAR-RESEARCH, 2005, V68, N2, NOV 1, pp 249-258 ISSN: 0008-6363.
Number of cited refs.
36 references.
6. Control of cancers by combining antiangiogenesis and cancer immunotherapy.
Author(s)
Moniz-M, Yeatermeyer-J, Wu-T-C.
Source
DRUGS-OF-TODAY, 2005, V41, N7, JUL, pp 471-494 ISSN: 0025-7656.
Number of cited refs.
212 references.
7. Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
Author(s)
Yao-B, He-Q-M, Tian-L, Xiao-F, Jiang-Y, Zhang-R, Li-G, Zhang-L, Hou-J- M, Wang-L, Cheng-X-C, Wen-Y-J, Kan-B, Li-J, Zhao-X, Hu-B, Zhou-Q, Zhang-L, Wei-Y-Q.
Source
HUMAN-GENE-THERAPY, 2005, V16, N9, SEP, pp 1075-1086 ISSN: 1043-0342.
Number of cited refs.
39 references.
8. Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
Author(s)
Hou-J-M, Liu-J-Y, Yang-L, Zhao-X, Tian-L, Ding-Z-Y, Wen-Y-J, Niu-T, Xiao-F, Lou-Y-Y, Tan-G-H, Deng-H-X, Li-J, Yang-J-L, Mao-Y-Q, Wei-Y-Q.
Source
ONCOLOGY, 2005, V69, N1, pp 81-87 ISSN: 0030-2414.
Number of cited refs.
21 references.
9. Transduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity.
Author(s)
Hu-J-Y, Li-G-C, Tong-Y-Q, Li-Y-H, Zhou-G-H, He-X-J, Xie-P-L, Wang-J-M, Sun-Q-B.
Source
INTERNATIONAL-IMMUNOPHARMACOLOGY, 2005, V5, N6, JUN, pp 971-980 ISSN: 1567-5769.
Number of cited refs.
40 references.
10. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor.
Author(s)
Hu-B, Wei-Y-Q, Tian-L, Zhao-X, Lu-Y, Wu-Y, Yao-B, Liu-J-Y, Niu-T, Wen- Y-J, He-Q-M, Su-J-M, Huang-M-J, Lou-Y-Y, Luo-Y, Kan-B.
Source
JOURNAL-OF-IMMUNOTHERAPY, 2005, V28, N3, MAY-JUN, pp 236-244 ISSN: 1524-9557.
Number of cited refs.
55 references.
11. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects.
Author(s)
Feng-K-K, Zhao-H-Y, Qiu-H, Liu-J-X, Chen-J.
Source
CANCER-LETTERS, 2005, V221, N1, APR 18, pp 41-47 ISSN: 0304-3835.
Number of cited refs.
24 references.
12. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
Author(s)
Pan-J, Heiser-A, Marget-M, Steinmann-J, Kabelitz-D.
Source
GENE-THERAPY, 2005, V12, N9, MAY, pp 742-750 ISSN: 0969-7128.
Number of cited refs.
35 references.
13. Role of endothelial cells in lung diseases.
Author(s)
Maitre-B.
Source
REVUE-DES-MALADIES-RESPIRATOIRES, 2004, V21, N5, 2, NOV, SS, pp S136- S137 ISSN: 0761-8425.
Number of cited refs.
5 references.
14. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer.
Feng-K-K, Zhao-H-Y, Hui-Q, Liu-J-X, Jian-C.
Source
CANCER-BIOTHERAPY-AND-RADIOPHARMACEUTICALS, 2004, V19, N5, OCT, pp 649-657 ISSN: 1084-9785.
Number of cited refs.
26 references.
15. Antigenic targets for renal cell carcinoma immunotherapy.
Author(s)
Vieweg-J, Jackson-A.
Source
EXPERT-OPINION-ON-BIOLOGICAL-THERAPY, 2004, V4, N11, NOV, pp 1791-1801 ISSN: 1471-2598.
Number of cited refs.
82 references.
16. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities.
Author(s)
Tan-G-H, Tian-L, Wei-Y-Q, Zhao-X, Li-J, Wu-Y, Wen-Y-J, Yi-T, Ding-Z-Y, Kan-B, Mao-Y-Q, Deng-H-X, Li-H-L, Zou-C-H, Fu-C-H.
Source
INTERNATIONAL-JOURNAL-OF-CANCER, 2004, V112, N4, NOV 20, pp 701-706 ISSN: 0020-7136.
Number of cited refs.
36 references.
17. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization.
Author(s)
Corsini-E, Gelati-M, Calatozzolo-C, Alessandri-G, Frigerio-S, De- Francesco-M, Poiesi-C, Parati-E, Croci-D, Boiardi-A, Salmaggi-A.
Source
CANCER-IMMUNOLOGY-IMMUNOTHERAPY, 2004, V53, N11, NOV, pp 955-962 ISSN: 0340-7004.
Number of cited refs.
26 references.
18. RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alpha(v)beta(3)-expressing endothelial cells.
Author(s)
Schraa-A-J, Kok-R-J, Botter-S-M, Withoff-S, Meuer-D-K-F, De-Leu-L-D-M- H, Molema-G.
Source
INTERNATIONAL-JOURNAL-OF-CANCER, 2004, V112, N2, NOV 1, pp 279-285 ISSN: 0020-7136.
Number of cited refs.
25 references.
19. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen.
Author(s)
Tan-G-H, Wei-Y-Q, Tian-L, Zhao-X, Yang-L, Li-J, He-Q-M, Wu-Y, Wen-Y-J, Yi-T, Ding-Z-Y, Kan-B, Mao-Y-Q, Deng-H-X, Li-H-L, Zhou-C-H, Fu-C-H, Xiao-F, Zhang-X-W.
Source
EUROPEAN-JOURNAL-OF-IMMUNOLOGY, 2004, V34, N7, JUL, pp 2012-2021 ISSN: 0014-2980.
Number of cited refs.
46 references.
20. Opinion - The promise of cancer vaccines.
Author(s)
Gilboa-E.
Source
NATURE-REVIEWS-CANCER, 2004, V4, N5, MAY, pp 401-411 ISSN: 1474-175X.
Number of cited refs.
150 references.
21. Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries.
Author(s)
Mutuberria-R, Satijn-S, Huijbers-A, van-der-Linden-E, Lichtenbeld-H, Chames-P, Arends-J-W, Hoogenboom-H-R.
Source
JOURNAL-OF-IMMUNOLOGICAL-METHODS, 2004, V287, N1-2, APR, pp 31-47 ISSN: 0022-1759.
Number of cited refs.
48 references.
22. Endothelial cell glycosylation: Regulation and modulation of biological processes.
Author(s)
Kieda-C, Dus-D.
Source
GLYCOBIOLOGY-AND-MEDICINE, 2003, V535, pp 79-94 ISSN: 0065-2598.
Number of cited refs.
122 references.
23. Functional endothelial cells derived from rhesus monkey embryonic stem cells.
Author(s)
Kaufman-D-S, Lewis-R-L, Hanson-E-T, Auerbach-R, Plendl-J, Thomson-J-A.
Source
BLOOD, 2004, V103, N4, FEB 15, pp 1325-1332 ISSN: 0006-4971.
Number of cited refs.
68 references.
24. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model.
Author(s)
Ishikawa-E, Tsuboi-K, Takano-S, Uchimura-E, Nose-T, Ohno-T.
Source
CANCER-SCIENCE, 2004, V95, N1, JAN, pp 98-103 ISSN: 1347-9032.
Number of cited refs.
47 references.
25. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity.
Author(s)
Okaji-Y, Tsuno-N-H, Kitayama-J, Saito-S, Takahashi-T, Kawai-K, Yazawa- K, Asakage-M, Hori-N, Watanabe-T, Shibata-Y, Takahashi-K, Nagawa-H.
Source
CANCER-SCIENCE, 2004, V95, N1, JAN, pp 85-90 ISSN: 1347-9032.
Number of cited refs.
35 references.
26. Immunotherapy of malignant diseases - Challenges and strategies.
Author(s)
Ko-E-C, Wang-X-H, Ferrone-S.
Source
INTERNATIONAL-ARCHIVES-OF-ALLERGY-AND-IMMUNOLOGY, 2003, V132, N4, pp 294-309 ISSN: 1018-2438.
Number of cited refs.
85 references.
27. Protective antitumor immunity induced by fixed tumor cells in combination with adjuvant in a murine hepatoma model.
Author(s)
Huang-L, Ohno-T.
Source
CANCER-LETTERS, 2003, V202, N2, DEC 30, pp 153-159 ISSN: 0304-3835.
Number of cited refs.
19 references.
28. Vaccination against angiogenesis-associated antigens: A novel cancer immunotherapy strategy.
Author(s)
Li-Y-W, Bohlen-P, Hicklin-D-J.
Source
CURRENT-MOLECULAR-MEDICINE, 2003, V3, N8, DEC, pp 773-779 ISSN: 1566-5240.
Number of cited refs.
31 references.
29. Cent strategies and future directions of antiangiogenic tumor therapy.
Author(s)
Zhang-Z-L, Wang-J-H, Liu-X-Y.
Source
ACTA-BIOCHIMICA-ET-BIOPHYSICA-SINICA, 2003, V35, N10, OCT, pp 873-880 ISSN: 0582-9879.
Number of cited refs.
64 references.
30. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2.
Author(s)
Liu-J-Y, Wei-Y-Q, Yang-L, Zhao-X, Tian-L, Hou-J-M, Niu-T, Liu-F, Jiang-Y, Hu-B, Wu-Y, Su-J-M, Lou-Y-Y, He-Q-M, Wen-Y-J, Yang-J-L, Kan- B, Mao-Y-Q, Luo-F, Peng-F.
Source
BLOOD, 2003, V102, N5, SEP 1, pp 1815-1823 ISSN: 0006-4971.
Number of cited refs.
58 references.
31. Adoptive immunotherapy for malignant glioma.
Author(s)
Mitchell-D-A, Fecci-P-E, Sampson-J-H.
Source
CANCER-JOURNAL, 2003, V9, N3, MAY-JUN, pp 157-166 ISSN: 1528-9117.
Number of cited refs.
100 references.
32. Synergy between tumor immunotherapy and antiangiogenic therapy.
Author(s)
Nair-S, Boczkowski-D, Moeller-B, Dewhirst-M, Vieweg-J, Gilboa-E.
Source
BLOOD, 2003, V102, N3, AUG 1, pp 964-971 ISSN: 0006-4971.
Number of cited refs.
51 references.
33. Advances in identification and application of tumor antigen inducing anti-cancer responses.
Author(s)
Xie-K, Tian-L, Deng-H-X, Wei-Y-Q.
Source
CHINESE-SCIENCE-BULLETIN, 2003, V48, N11, JUN, pp 1051-1054 ISSN: 1001-6538.
Number of cited refs.
40 references.
34. The therapeutic potential of novel antiangiogenic therapies.
Author(s)
Scappaticci-F-A.
Source
EXPERT-OPINION-ON-INVESTIGATIONAL-DRUGS, 2003, V12, N6, JUN, pp 923-932 ISSN: 1354-3784.
Number of cited refs.
63 references.
35. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine.
Author(s)
Scappaticci-F-A, Nolan-G-P.
Source
ANTICANCER-RESEARCH, 2003, V23, N2B, MAR-APR, pp 1165-1172 ISSN: 0250-7005.
Number of cited refs.
34 references.
36. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice.
Author(s)
He-Q-M, Wei-Y-Q, Tian-L, Zhao-X, Su-J-M, Yang-L, Lu-Y, Kan-B, Lou-Y-Y, Huang-M-J, Xiao-F, Liu-J-Y, Hu-B, Luo-F, Jiang-Y, Wen-Y-J, Deng-H-X, Li-J, Niu-T, Yang-J-L.
Source
JOURNAL-OF-BIOLOGICAL-CHEMISTRY, 2003, V278, N24, JUN 13, pp 21831-21836 ISSN: 0021-9258.
Number of cited refs.
49 references.
37. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice.
Author(s)
Scappaticci-F-A, Contreras-A, Boswell-C-A, Lewis-J-S, Nolan-G.
Source
VACCINE, 2003, V21, N19-20, JUN 2, pp 2667-2677 ISSN: 0264-410X.
Number of cited refs.
35 references.
38. How endothelial cell organo-specificity mediates circulating cell homing.
Author(s)
Kieda-C.
Source
ARCHIVUM-IMMUNOLOGIAE-ET-THERAPIAE-EXPERIMENTALIS, 2003, V51, N2, pp 81-89 ISSN: 0004-069X.
Number of cited refs.
123 references.
39. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.
Author(s)
Lu-Y, Wei-Y-Q, Tian-L, Zhao-X, Yang-L, Hu-B, Kan-B, Wen-Y-J, Liu-F, Deng-H-X, Li-J-O, Mao-Y-Q, Lei-S, Huang-M-J, Peng-F, Jiang-Y, Zhou-H, Zhou-L-Q, Luo-F.
Source
JOURNAL-OF-IMMUNOLOGY, 2003, V170, N6, MAR 15, pp 3162-3170. ISSN: 0022-1767.
Number of cited refs.
59 references.
40. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2.
Author(s)
Su-J-M, Wei-Y-Q, Tian-L, Zhao-X, Yang-L, He-Q-M, Wang-Y, Lu-Y, Wu-Y, Liu-F, Liu-J-Y, Yang-J-L, Lou-Y-Y, Hu-B, Niu-T, Wen-Y-J, Xiao-F, Deng- H-X, Li-J, Kan-B.
Source
CANCER-RESEARCH, 2003, V63, N3, FEB 1, pp 600-607. ISSN: 0008-5472.
Number of cited refs.
44 references.
41. Vaccination against tumor neovascularization: Promise and reality.
Author(s)
Rafii-S.
Source
CANCER-CELL, 2002, V2, N6, DEC, pp 429-431. ISSN: 1535-6108.
Number of cited refs.
10 references.
42. Adjuvant effect of a flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model.
Author(s)
Kim-E-M, Sivanandham-M, Stavropoulos-C-I, Wallack-M-K.
Source
JOURNAL-OF-SURGICAL-RESEARCH, 2002, V108, N1, NOV, pp 148-156. ISSN: 0022-4804.
Number of cited refs.
61 references.
43. Mechanisms and future directions for angiogenesis-based cancer therapies.
Author(s)
Scappaticci-F-A.
Source
JOURNAL-OF-CLINICAL-ONCOLOGY, 2002, V20, N18, SEP 15, pp 3906-3927. ISSN: 0732-183X.
Number of cited refs.
231 references.
44. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
Author(s)
Xiao-F, Wei-Y, Yang-L, Zhao-X, Tian-L, Ding-Z, Yuan-S, Lou-Y, Liu-F, Wen-Y, Li-J, Deng-H, Kang-B, Mao-Y, Lei-S, He-Q, Su-J, Lu-Y, Niu-T, Hou-J, Huang-M-J.
Source
GENE-THERAPY, 2002, V9, N18, SEP, pp 1207-1213. ISSN: 0969-7128.
Number of cited refs.
44 references.
45. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.
Author(s)
Li-Y-W, Wang-M-N, Li-H-L, King-K-D, Bassi-R, Sun-H-J, Santiago-A, Hooper-A-T, Bohlen-P, Hicklin-D-J.
Source
JOURNAL-OF-EXPERIMENTAL-MEDICINE, 2002, V195, N12, JUN 17, pp 1575-1584. ISSN: 0022-1007.
Number of cited refs.
40 references.
46. Immunogene therapy of tumors with a vaccine based on the ligand- binding domain of chicken homologous integrin beta(3).
Author(s)
Lou-Y-Y, Wei-Y-Q, Yang-L, Zhao-X, Tian-L, Lu-Y, Wen-Y-J, Liu-F, Huang- M-J, Kang-B, Xiao-F, Su-J-M, He-Q-M, Xie-X-J, Mao-Y-Q, Lei-S, Liu-J-Y, Lou-F, Zhou-L-Q, Peng-F, Jiang-Y, Hu-B.
Source
IMMUNOLOGICAL-INVESTIGATIONS, 2002, V31, N1, pp 51-69. ISSN: 0882-0139.
Number of cited refs.
45 references.
47. Monoclonal and polyclonal humoral immune response to EC HER-2/neu peptides with low similarity to the host's proteome.
Author(s)
Mittelman-A, Lucchese-A, Sinha-A-A, Kanduc-D.
Source
INTERNATIONAL-JOURNAL-OF-CANCER, 2002, V98, N5, APR 10, pp 741-747. ISSN: 0020-7136.
Number of cited refs.
33 references.
48. Xenogeneic homologous genes, molecular evolution and cancer therapy.
Author(s)
Tian-L, Wei-Y-Q.
Source
PROGRESS-IN-NATURAL-SCIENCE, 2001, V11, N12, DEC, pp 893-904. ISSN: 1002-0071.
Number of cited refs.
27 references.
49. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
Author(s)
Wei-Y-Q, Huang-M-J, Yang-L, Zhao-X, Tian-L, Lu-Y, Shu-J-M, Lu-C-J, Niu-T, Kang-B, Mao-Y-Q, Liu-F, Wen-Y-J, Lei-S, Luo-F, Zhou-L-Q, Peng- F, Jiang-Y, Liu-J-Y, Zhou-H, Wang-Q-R, He-Q-M, Xiao-F, Lou-Y-Y, Xie-X- J, Li-Q, Wu-Y, Ding-Z-Y, Hu-B, Hu-M, Zhang-W.
Source
PROCEEDINGS-OF-THE-NATIONAL-ACADEMY-OF-SCIENCES-OF-THE-UNITED-STATES- OF-AMERICA, 2001, V98, N20, SEP 25, pp 11545-11550. ISSN: 0027-8424.
Number of cited refs.
51 references.
50. An animal model of autoimmune emphysema.
Author(s)
Taraseviciene-Stewart-L, Scerbavicius-R, Chloe-K-H, Moore-M, Sullivan- A, Nicolls-M-R, Fontenot-A-P, Tuder-R-M, Voelkel-N-F.
Source
AMERICAN-JOURNAL-OF-RESPIRATORY-AND-CRITICAL-CARE-MEDICINE, 2005, V171, N7, APR 1, pp 734-742 ISSN: 1073-449X.
Number of cited refs.
57 references.
51. Antibody phage display technologies with special reference to angiogenesis.
Author(s)
Smith-J, Kontermann-R-E, Embleton-J, Kumar-S.
Source
FASEB-JOURNAL, 2005, V19, N3, MAR, pp 331-341 ISSN: 0892-6638.
Number of cited refs.
107 references.
52. Immunotherapy of tumor by targeting angiogenesis.
Author(s)
Hou-J-M, Tian-L, Wei-Y-Q.
Source
SCIENCE-IN-CHINA-SERIES-C-LIFE-SCIENCES, 2004, V47, N6, DEC, pp 545-552 ISSN: 1006-9305.
Number of cited refs.
43 references.
53. Modulation of antitumor responses by dendritic cells.
Author(s)
Vieweg-J, Jackson-A.
Source
SPRINGER-SEMINARS-IN-IMMUNOPATHOLOGY, 2005, V26, N3, JAN, pp 329-341 ISSN: 0344-4325.
Number of cited refs.
79 references.
54. Soluble low-molecular-mass tumor-associated proteins promote the suppression of mammary tumors by cyclophosphamide.
Author(s)
Ben-Hur-H, Kossoy-G, Zusman-I.
Source
INTERNATIONAL-JOURNAL-OF-ONCOLOGY, 2001, V19, N2, AUG, pp 407-411 ISSN: 1019-6439.
Number of cited refs.
25 references.
55. Bone marrow-derived endothelial cells for therapeutic angiogenesis and antiangiogenesis: Facts and visions.
Author(s)
Gunsilius-E.
Source
JOURNAL-OF-HEMATOTHERAPY-STEM-CELL-RESEARCH, 2002, V11, N1, FEB, pp 153-155 ISSN: 1525-8165.
Number of cited refs.
16 references.
56. Targeting tumor angiogenesis with gene therapy.
Author(s)
Chen-Q-R, Zhang-L, Gasper-W, Mixson-A-J.
Source
MOLECULAR-GENETICS-AND-METABOLISM, 2001, V74, N1-2, SEP-OCT, pp 120-127 ISSN: 1096-7192.
Number of cited refs.
64 references.
57. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules.
Author(s)
Wei-Y-Q.
Source
ANTI-CANCER-DRUGS, 2002, V13, N3, MAR, pp 229-235 ISSN: 0959-4973.
Number of cited refs.
48 references.